The Role of Androgen Receptor Expression in Prostate Adenocarcinoma

Hermien Hermien; Husni Cangara; Upik A. Miskad; Andi Alfian Zainuddin; Abdul Azis; Djumadi Achmad; Mahmud Ghaznawie

doi:10.3889/oamjms.2022.9300

Authors

Hermien Hermien Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Husni Cangara Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Upik A. Miskad Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Andi Alfian Zainuddin Department of Public Health and Community, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Abdul Azis Department of Surgery, Division of Urology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Djumadi Achmad Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Mahmud Ghaznawie Department of Anatomical Pathology, Faculty of Medicine, Muhammadiyah Makassar University, Makassar, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9300

Keywords:

Androgen receptor, Prostate adenocarcinoma, WHO grade group

Abstract

Prostate cancer is one of the most common cancer worldwide, where South Sulawesi is included in four provinces with the highest prevalence of prostate cancer in Indonesia. Laboratorium Sentra Patologia Makassar (SDPM) stated that prostate cancer cases continue to rise each year. Androgen receptor (AR) plays a role in the growth and differentiation of male urogenital structures, both under normal and neoplastic conditions, the neoplastic condition is caused by the mechanism of the AR pathway which undergoes changes that continue in the development and progression of prostate lesions, both benign and malignant. Androgen receptors are generally found evenly distributed in the nuclei of glandular and stromal cells in prostate hyperplasia and vary widely in prostate cancer. These inventions show that AR inhibitors are used to treat prostate adenocarcinoma by inhibiting androgen synthesis. Assessment of AR expression can be used in determining therapy and predicting the success of hormonal therapy so that the prognosis of the disease is better. This study is conducted to learn more about AR expression in adenocarcinoma prostate grading. The type of this research is an observational analytical study with cross-sectional methods. Samples are taken based on consecutive sampling of as many as 77 respondents. There is a significant difference between AR expression score and histopathological feature of prostate adenocarcinoma WHO Grup Grade (p<0,001). In conclusion, there is a significant correlation between AR and WHO Grup Grade and could be used as important marker in grading adenocarcinoma prostate progression

Keywords : Androgen receptor (AR); prostate adenocarcinoma; WHO Grup Grade

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593 DOI: https://doi.org/10.3322/caac.21492

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. https://doi.org/10.1002/ijc.31937 PMid:30350310 DOI: https://doi.org/10.1002/ijc.31937

Humphrey PA. Histopathology of prostate cancer. Cold Spring Harbor Perspect Med. 2017;7(10):a030411. https://doi.org/10.1101/cshperspect.a030411 PMid:28389514 DOI: https://doi.org/10.1101/cshperspect.a030411

Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001;93(22):1687-97. https://doi.org/10.1093/jnci/93.22.1687 PMid:11717329 DOI: https://doi.org/10.1093/jnci/93.22.1687

Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Rel Cancer. 2008;15(4):841-9. https://doi.org/10.1677/ERC-08-0084 PMid:18667687 DOI: https://doi.org/10.1677/ERC-08-0084

Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the Type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002;62(10):2942-50. PMid:12019176 DOI: https://doi.org/10.1016/S1569-9056(02)80120-8

Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2009;23(2):205-12. http://doi.org/10.1038/modpathol.2009.159 PMid:19898421 DOI: https://doi.org/10.1038/modpathol.2009.159

Velcheti V, Karnik S, Bardot SF, Prakash O. Pathogenesis of prostate cancer: Lessons from basic research. Ochsner J. 2008;8(4):213-8. PMid:21603505

Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20(Suppl 3):S11-8. https://doi.org/10.1038/ijir.2008.55 PMid:19002119 DOI: https://doi.org/10.1038/ijir.2008.55

Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276-308. https://doi.org/10.1210/er.2002-0032 PMid:15082523 DOI: https://doi.org/10.1210/er.2002-0032

Hashmi AA, Mudassir G, Irfan M, Hussain ZF, Hashmi SK, Asif H, et al. Prognostic significance of high androgen receptor expression in prostatic acinar adenocarcinoma. Asian Pac J Cancer Prev. 2019;20(3):893-6. https://doi.org/10.31557/APJCP.2019.20.3.893 PMid:30912411 DOI: https://doi.org/10.31557/APJCP.2019.20.3.893

Putriyuni A, Oktora MZ. Androgen receptor expression of prostate cancer correlates with gleason score and perineural invasion in West Sumatera, Indonesia. Int J Med Sci Clin Invent. 2020;7(11):5125-9. https://doi.org/10.18535/ijmsci/v7i11.010 DOI: https://doi.org/10.18535/ijmsci/v7i11.010